Stock MIPH MINAPHARM PHARMACEUTICALS
Add to a list
To use this feature you must be a member
Log inSign up

MINAPHARM Pharmaceuticals Stock

Equities

MIPH

EGS380G1C011

Pharmaceuticals

End-of-day quote Egyptian Exchange
Other stock markets
 06:00:00 2024-06-02 pm EDT 		5-day change 1st Jan Change
213.5 EGP 0.00% Intraday chart for MINAPHARM Pharmaceuticals +6.61% -1.92%
May. 30 MINAPHARM Pharmaceuticals Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 07 MINAPHARM Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Financials

Sales 2022 3.62B 76.43M Sales 2023 3.89B 82.16M Capitalization 2.41B 50.84M
Net income 2022 613M 12.94M Net income 2023 -32M -676K EV / Sales 2022 0.71 x
Net Debt 2022 740M 15.61M Net Debt 2023 1.89B 39.87M EV / Sales 2023 1.1 x
P/E ratio 2022
2.88 x
P/E ratio 2023
-43.5 x
Employees -
Yield 2022
1.89%
Yield 2023
0.76%
Free-Float 19.26%
More Fundamentals * Assessed data

Chart MINAPHARM Pharmaceuticals

Dynamic Chart

Latest news about MINAPHARM Pharmaceuticals

MINAPHARM Pharmaceuticals Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
MINAPHARM Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2023 CI
MINAPHARM Pharmaceuticals Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
MINAPHARM Pharmaceuticals Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
MINAPHARM Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Bioventure, Minapharm Pharmaceuticals and Migentra Sign an Exclusive Agreement for the Commercialization of Multiple Biosimilar Candidates of Alvotech in the Middle East and Africa CI
MINAPHARM Pharmaceuticals Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
MINAPHARM Pharmaceuticals Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
MINAPHARM Pharmaceuticals Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
MINAPHARM Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2021 CI
MINAPHARM Pharmaceuticals Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
MINAPHARM Pharmaceuticals Reports Consolidated Earnings Results for the Six Months Ended June 30, 2021 CI
MINAPHARM Pharmaceuticals Reports Standalone Earnings Results for the Six Months Ended June 30, 2021 CI
MINAPHARM Pharmaceuticals Announces Consolidated Earnings Results for the Quarter Ended March 31, 2021 CI
ProBioGen AG and MINAPHARM Pharmaceuticals Incorporate MiGenTra GmbH - A Healthcare Transforming Medicines Company CI
More news

Press releases MINAPHARM Pharmaceuticals

SaudiVax, Minapharm, and MiGenTra Sign a Memorandum of Understanding towards a Strategic Partnership in Saudi Arabia and the Gulf Cooperation Countries AQ
SaudiVax, Minapharm, and MiGenTra Sign a Memorandum of Understanding towards a Strategic Partnership in Saudi Arabia and the Gulf Cooperation Countries This landmark MOU marks a significant step towards ensuring national health security and achieving biomanufacturing autonomy in Saudi Arabia AQ
Participants Dosed of Adessia® in Germany in a Phase 1 Trial, a First for an Adalimumab Biosimilar Candidate Developed in Africa AQ
Participants Dosed of Adessia® in Germany in a Phase 1 Trial, a First for an Adalimumab Biosimilar Candidate Developed in Africa This follows a prior announcement made by Minapharm Pharmaceuticals on February 13, 2023 reporting that said Phase 1 trial received unconditional approval from the Paul-Ehrlich Institut (PEI) AQ
Bioventure, Minapharm Pharmaceuticals and MiGenTra Sign an Exclusive Agreement for the Commercialization of Multiple Biosimilar Candidates of Alvotech in the Middle East and Africa AQ
More press releases

Quotes and Performance

1 week+6.61%
1 month+6.61%
3 months-16.00%
6 months-9.64%
Current year-1.92%
More quotes

Highs and lows

1 week
193.20
Extreme 193.2
215.00
1 month
165.44
Extreme 165.44
215.99
Current year
165.44
Extreme 165.44
294.70
1 year
165.44
Extreme 165.44
294.70
3 years
94.00
Extreme 94
294.70
5 years
64.00
Extreme 64
294.70
10 years
25.70
Extreme 25.7
294.70
More quotes

Managers and Directors - MINAPHARM Pharmaceuticals

Managers TitleAgeSince
Shaheer Wafeeq Sa'ad Al-Bardissy CEO
 Chief Executive Officer - -
Wafik Saad El-Bardissy CEO
 Chief Executive Officer - -
Rafiq Raymond DFI
 Director of Finance/CFO - -
Members of the board TitleAgeSince
Amr Mohamed Sobhi Hamza El-Shabrawishy BRD
 Director/Board Member - -
Wafik Saad El-Bardissy CEO
 Chief Executive Officer - -
Anwar Nasr Mekhaeel BRD
 Director/Board Member - -
More insiders

Quotes

Date Price Change Volume
24-06-03 213.5 0.00% 584
24-06-02 213.5 0.00% 272
24-05-30 213.5 0.00% 52
24-05-29 213.5 +6.61% 2,228
24-05-28 200.3 0.00% 196

End-of-day quote Egyptian Exchange, June 02, 2024

More quotes

Company Profile

Minapharm Pharmaceuticals S.A.E. specializes in developing, manufacturing and marketing prescription pharmaceutical products. The products are for the treatment of gastroenterological, ophthalmologic, cardiovascular, genetic, dermatological, orthopedic diseases, etc.
Sector
Pharmaceuticals
More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

1st Jan change Capi.
MINAPHARM PHARMACEUTICALS Stock MINAPHARM Pharmaceuticals
-1.92% 50.1M
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+13.53% 41.95B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+22.20% 22.53B
SANDOZ GROUP AG Stock Sandoz Group AG
+15.59% 14.91B
CIPLA LIMITED Stock Cipla Limited
+17.35% 14.11B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+45.62% 12.5B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-9.44% 6.75B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+14.55% 5.6B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. MIPH Stock